Hillhouse Capital Management, Ltd. - Net Worth and Insider Trading

Hillhouse Capital Management, Ltd. Net Worth

The estimated net worth of Hillhouse Capital Management, Ltd. is at least $291 Million dollars as of 2025-06-07. Hillhouse Capital Management, Ltd. is the 2102 Investment manager of Jacobio Pharmaceuticals Group Co Ltd and owns about 56,861,110 shares of Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) stock worth over $291 Million. Details can be seen in Hillhouse Capital Management, Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Hillhouse Capital Management, Ltd. has not made any transactions after 2020-12-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Hillhouse Capital Management, Ltd.

Hillhouse Capital Management, Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Hillhouse Capital Management, Ltd. owns 1 companies in total, including Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) .

Click here to see the complete history of Hillhouse Capital Management, Ltd.’s form 4 insider trades.

Insider Ownership Summary of Hillhouse Capital Management, Ltd.

Ticker	Company	Transaction Date	Type of Owner
HKSE:01167	Jacobio Pharmaceuticals Group Co Ltd	2020-12-21	2102 Investment manager

Hillhouse Capital Management, Ltd. Latest Holdings Summary

Hillhouse Capital Management, Ltd. currently owns a total of 1 stock. Hillhouse Capital Management, Ltd. owns 56,861,110 shares of Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) as of December 21, 2020, with a value of $291 Million.

Latest Holdings of Hillhouse Capital Management, Ltd.

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:01167	Jacobio Pharmaceuticals Group Co Ltd	2020-12-21	56,861,110	5.11	290,560,272

Holding Weightings of Hillhouse Capital Management, Ltd.

Hillhouse Capital Management, Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Hillhouse Capital Management, Ltd. has made a total of 1 transactions in Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in Jacobio Pharmaceuticals Group Co Ltd is the sale of 0 shares on December 21, 2020, which brought Hillhouse Capital Management, Ltd. around $0.

Insider Trading History of Hillhouse Capital Management, Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Hillhouse Capital Management, Ltd. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Hillhouse Capital Management, Ltd. Ownership Network

Ownership Network List of Hillhouse Capital Management, Ltd.

No Data

Ownership Network Relation of Hillhouse Capital Management, Ltd.

Hillhouse Capital Management, Ltd. Owned Company Details

What does Jacobio Pharmaceuticals Group Co Ltd do?

Who are the key executives at Jacobio Pharmaceuticals Group Co Ltd?

Hillhouse Capital Management, Ltd. is the 2102 Investment manager of Jacobio Pharmaceuticals Group Co Ltd. Other key executives at Jacobio Pharmaceuticals Group Co Ltd include 2501 Other Yakovpharma Ltd , 2501 Other Wang Yinxiang , and 2501 Other Blesspharma Ltd .

Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) Insider Trades Summary

Over the past 18 months, Hillhouse Capital Management, Ltd. made no insider transaction in Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167). Other recent insider transactions involving Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) include a net sale of 0 shares made by Wang Yinxiang , a net sale of 0 shares made by Hu Yunyan , and a net sale of 0 shares made by Wang Xiaojie .

In summary, during the past 3 months, insiders sold 0 shares of Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 647,316 shares of Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167) were sold and 0 shares were bought by its insiders, resulting in a net sale of 647,316 shares.

Jacobio Pharmaceuticals Group Co Ltd (HKSE:01167)'s detailed insider trading history can be found in Insider Trading Tracker table.

Jacobio Pharmaceuticals Group Co Ltd Insider Transactions

No Available Data

Hillhouse Capital Management, Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Hillhouse Capital Management, Ltd.. Currently GuruFocus does not have mailing address information for Hillhouse Capital Management, Ltd..

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.